The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Anti-CD20 Monoclonal Antibodies Market Between 2026 And 2030?
The anti-cd20 monoclonal antibodies market size has shown significant expansion in recent years. This market is anticipated to increase from $9 billion in 2025 to $9.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The historical growth can be attributed to several factors, including the approval and extensive use of rituximab, the increasing incidence of non-hodgkin’s lymphoma and chronic lymphocytic leukemia, a growing understanding of targeted therapies, the presence of hospital pharmacy distribution channels, and the development of intravenous administration routes.
The anti-cd20 monoclonal antibodies market is expected to demonstrate significant expansion in the coming years, reaching $12.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is attributed to several factors, including the development of obinutuzumab and ofatumumab biosimilars, an increase in the adoption of subcutaneous formulations, rising investment in research and academia, the expansion of ambulatory care centers, and a growing demand for anti-cd20 therapies in various autoimmune diseases. Prominent trends for this period include the increasing uptake of monoclonal antibody therapies for B-cell malignancies, the development of biosimilars and advanced anti-cd20 antibodies, the proliferation of subcutaneous and patient-friendly administration routes, a heightened focus on personalized and targeted immunotherapy, and a surge in clinical trials and research across autoimmune and oncology indications.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp
Which Factors Are Influencing The Growth Of The Anti-CD20 Monoclonal Antibodies Market?
The increasing incidence of autoimmune conditions is anticipated to drive expansion in the anti-CD20 monoclonal antibodies market. These conditions arise when the immune system mistakenly targets the body’s own cells, perceiving them as harmful and initiating an assault. A rise in autoimmune diseases is linked to increased exposure to environmental contaminants, which can disrupt immune system regulation and provoke attacks on bodily tissues. Anti-CD20 monoclonal antibodies address autoimmune diseases by eradicating B cells, which are responsible for generating autoantibodies and causing inflammation. Their function is to modulate the immune response and alleviate symptoms associated with these diseases. As an illustration, data from Arthritis Australia, a non-profit organization located in Australia, indicated in February 2024 that approximately 562,378 Australians are projected to have RA in 2025, making up 14% of all arthritis diagnoses for that year. This figure is forecast to climb by 33% to reach 748,721 individuals by 2040, signifying an increase of 186,343 Australians affected by RA in 2040 compared to 2025. Consequently, the escalating prevalence of autoimmune diseases is fueling the expansion of the anti-CD20 monoclonal antibodies market.
How Are Segments Identified Within The Anti-CD20 Monoclonal Antibodies Market Segment Framework?
The anti-cd20 monoclonal antibodies market covered in this report is segmented –
1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications
5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users
Subsegments:
1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux
2) By Obinutuzumab: Gazyva, Biosimilar Candidates
3) By Ofatumumab: Arzerra, Kesimpta
4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab
Which Trends Are Shaping Growth In The Anti-CD20 Monoclonal Antibodies Market?
Major companies operating in the anti-CD20 monoclonal antibody market are concentrating on developing advanced products such as obinutuzumab to target resistant or relapsed B-cell malignancies more effectively. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody engineered to specifically target and eliminate CD20-positive B cells involved in certain blood cancers and autoimmune diseases. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced that the US Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for the treatment of lupus nephritis. This decision is based on positive results from the Phase III REGENCY study, which showed an improved complete renal response (CRR) when combined with standard therapy compared to standard therapy alone. This positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to demonstrate such benefit in lupus nephritis, a severe inflammation caused by lupus that can lead to kidney failure.
Who Are The Companies Competing Within The Anti-CD20 Monoclonal Antibodies Market?
Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.
Get The Full Anti-CD20 Monoclonal Antibodies Market Report:
Which Region Holds The Highest Market Share In The Anti-CD20 Monoclonal Antibodies Market?
North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Anti-CD20 Monoclonal Antibodies Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2026, By The Business Research Company
Monoclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Monoclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Polyclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model